Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Acquired by BNP Paribas Financial Markets

BNP Paribas Financial Markets boosted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 92.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 79,939 shares of the company’s stock after acquiring an additional 38,427 shares during the period. BNP Paribas Financial Markets’ holdings in Medpace were worth $26,684,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in MEDP. Signaturefd LLC raised its position in Medpace by 4.9% in the second quarter. Signaturefd LLC now owns 559 shares of the company’s stock valued at $230,000 after purchasing an additional 26 shares during the period. Wealth Alliance raised its holdings in Medpace by 2.9% in the 2nd quarter. Wealth Alliance now owns 970 shares of the company’s stock valued at $399,000 after buying an additional 27 shares during the period. Centaurus Financial Inc. lifted its position in Medpace by 2.0% in the third quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock valued at $505,000 after buying an additional 29 shares during the last quarter. Commonwealth Equity Services LLC boosted its stake in Medpace by 0.7% during the second quarter. Commonwealth Equity Services LLC now owns 4,340 shares of the company’s stock worth $1,787,000 after buying an additional 32 shares during the period. Finally, Lindenwold Advisors INC increased its position in shares of Medpace by 1.6% during the third quarter. Lindenwold Advisors INC now owns 2,026 shares of the company’s stock valued at $676,000 after acquiring an additional 32 shares during the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

MEDP has been the subject of a number of research analyst reports. StockNews.com cut shares of Medpace from a “buy” rating to a “hold” rating in a research report on Friday, September 27th. Redburn Atlantic started coverage on Medpace in a research note on Monday, October 14th. They issued a “buy” rating and a $404.00 price objective for the company. Truist Financial decreased their target price on Medpace from $415.00 to $397.00 and set a “hold” rating on the stock in a research note on Monday, October 14th. Robert W. Baird lifted their target price on Medpace from $349.00 to $354.00 and gave the company a “neutral” rating in a research report on Monday, November 25th. Finally, William Blair reissued an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $380.56.

Medpace Stock Up 0.5 %

Shares of NASDAQ:MEDP opened at $340.63 on Friday. Medpace Holdings, Inc. has a fifty-two week low of $268.80 and a fifty-two week high of $459.77. The firm’s 50 day moving average price is $337.82 and its 200 day moving average price is $371.41. The stock has a market cap of $10.59 billion, a price-to-earnings ratio of 29.83, a price-to-earnings-growth ratio of 1.88 and a beta of 1.37.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.24. The business had revenue of $533.32 million during the quarter, compared to analysts’ expectations of $540.99 million. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The company’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same period in the previous year, the company earned $2.22 EPS. On average, equities analysts anticipate that Medpace Holdings, Inc. will post 11.93 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.